July 27, 2016 7:19 PM ET


Company Overview of LFB S.A.

Company Overview

LFB S.A., a biopharmaceutical company, develops, manufactures, and markets medicinal products for the treatment of serious and rare diseases in the therapeutic areas of immunology, haemostasis, and intensive care worldwide. Its products include plasma-derived, recombinant, and cell therapy medicinal products. The company offers therapeutic solutions to treat primary immuno-deficiency, autoimmune diseases, and acquired troubles, such as secondary immuno-deficiency; and constitutional bleeding disorders, as well as biomedicines to treat patients who are often in a critical condition due to severe deficiencies in essential plasma proteins. It is also involved in the services and intermediate bi...

3, Avenue des Tropiques

B.P. 305

Courtabœuf Cedex

Les Ulis,  91958


Founded in 1994

2,111 Employees


33 1 69 82 70 10


33 1 69 07 19 03

Key Executives for LFB S.A.

Chairman, Chief Executive Officer, Chairman of LFB Biotechnologies and Chief Executive Officer of LFB Biomedicaments
Age: 56
Executive Vice-President of Finance & Strategy
Chief Executive Officer of LFB Hemoderivados E Biotecnologia Ltda, Brazil
Sales Director and Executive Vice-President of Global Marketing & Sales - Lfb Biomedicaments Sa
Managing Director of Europlasma AT GmbH
Compensation as of Fiscal Year 2016.

LFB S.A. Key Developments

LFB S.A. Reports Consolidated Earnings Results for 2015

LFB S.A. reported consolidated earnings results for 2015. The company reported turnover of EUR 502.4 million, operational earnings of EUR 12 million, net earnings of EUR 0.3 million against turnover of EUR 501.9 million, operational earnings of EUR 25.2 million, net earnings of EUR 13 million a year ago.

LFB S.A. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016

LFB S.A. Presents at 13th Annual BIO Asia International Conference 2016, Mar-15-2016 . Venue: Grand Hyatt, Tokyo, Japan.

Knight Therapeutics Inc. and LFB S.A. Announce Filing Of New Drug Submission for Atryn(r)

Knight Therapeutics Inc. and LFB S.A. announced that Knight's New Drug Submission (NDS) has been accepted for review by Health Canada for ATryn(r) [Antithrombin (Recombinant)] for the prevention of peri-operative and peri-partum thromboembolic events in hereditary antithrombin deficient patients.

Similar Private Companies By Industry

Company Name Region
Acticor Biotech S.A.S. Europe
Ademtech SA Europe
Aelis Farma S.A.S. Europe
Aenitis Technologies SAS Europe
Alderys SAS Europe

Recent Private Companies Transactions

July 8, 2016
C.A.F.-D.C.F. bvba-sprl

The information and data displayed in this profile are created and managed by Capital IQ, a Standard & Poor's company. Bloomberg.com does not create or control the content. For inquiries, please contact Capital IQ directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact LFB S.A., please visit www.lfb.fr. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.